PubMed

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.

Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH.

Diabetes Care. 2005 Sep;28(9):2106-12.PMID: 16123474 [PubMed - indexed for MEDLINE]Related articlesFree article

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.

Rossing K, Jacobsen P, Pietraszek L, Parving HH.

Diabetes Care. 2003 Aug;26(8):2268-74.PMID: 12882847 [PubMed - indexed for MEDLINE]Related articlesFree article

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

Rossing K, Christensen PK, Jensen BR, Parving HH.

Diabetes Care. 2002 Jan;25(1):95-100.PMID: 11772908 [PubMed - indexed for MEDLINE]Related articlesFree article

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH.

Kidney Int. 2006 Aug;70(3):536-42. Epub 2006 Jun 14.PMID: 16775595 [PubMed - indexed for MEDLINE]Related articles

Beneficial impact of spironolactone in diabetic nephropathy.

Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH.

Kidney Int. 2005 Dec;68(6):2829-36.PMID: 16316360 [PubMed - indexed for MEDLINE]Related articles

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.

Nephrol Dial Transplant. 2002 Jun;17(6):1019-24.PMID: 12032191 [PubMed - indexed for MEDLINE]Related articlesFree article

Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.

Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH.

Diabetes Care. 2003 Jan;26(1):150-5.PMID: 12502672 [PubMed - indexed for MEDLINE]Related articlesFree article

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.

Jacobsen P, Andersen S, Jensen BR, Parving HH.

J Am Soc Nephrol. 2003 Apr;14(4):992-9.PMID: 12660333 [PubMed - indexed for MEDLINE]Related articlesFree article

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.

van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.

J Hypertens. 2006 Nov;24(11):2285-92.PMID: 17053552 [PubMed - indexed for MEDLINE]Related articles

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.

Kidney Int. 2003 May;63(5):1874-80.PMID: 12675866 [PubMed - indexed for MEDLINE]Related articles

Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.

Schjoedt KJ, Astrup AS, Persson F, Frandsen E, Boomsma F, Rossing K, Tarnow L, Rossing P, Parving HH.

Diabetologia. 2009 Jan;52(1):46-9. Epub 2008 Oct 31.PMID: 18974967 [PubMed - indexed for MEDLINE]Related articles

Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.

Saklayen MG, Gyebi LK, Tasosa J, Yap J.

J Investig Med. 2008 Apr;56(4):714-9.PMID: 18382267 [PubMed - indexed for MEDLINE]Related articles

Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.

Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH.

Diabetes Care. 2000 Dec;23(12):1725-30.PMID: 11128341 [PubMed - indexed for MEDLINE]Related articlesFree article

Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.

Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH.

Diabetes. 1997 Mar;46(3):481-7.PMID: 9032106 [PubMed - indexed for MEDLINE]Related articles

Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.

Lacourcière Y, Bélanger A, Godin C, Hallé JP, Ross S, Wright N, Marion J.

Kidney Int. 2000 Aug;58(2):762-9.PMID: 10916100 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH.

Diabetes Care. 2003 May;26(5):1501-6.PMID: 12716812 [PubMed - indexed for MEDLINE]Related articlesFree article

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH.

Kidney Int. 2005 Sep;68(3):1190-8.PMID: 16105050 [PubMed - indexed for MEDLINE]Related articles

Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH.

Kidney Int. 2002 Jul;62(1):192-8.PMID: 12081578 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy.

Bauer JH, Reams GP, Hewett J, Klachko D, Lau A, Messina C, Knaus V.

Am J Kidney Dis. 1992 Nov;20(5):443-57.PMID: 1442757 [PubMed - indexed for MEDLINE]Related articles

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.

Kidney Int. 2000 Feb;57(2):601-6.PMID: 10652037 [PubMed - indexed for MEDLINE]Related articlesFree article